Literature DB >> 22842073

MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus.

John H Anneken1, Gary A Gudelsky.   

Abstract

The neurochemical effects of MDMA (3,4-methylenedioxymethamphetamine) on monoaminergic and cholinergic systems in the rat brain have been well documented. However, little is known regarding the effects of MDMA on glutamatergic systems in the brain. In the present study the effects of multiple injections of MDMA on extracellular concentrations of glutamate in the striatum, prefrontal cortex, and dorsal hippocampus were examined. Two or four, but not one, injections of MDMA (10 mg/kg, i.p. at 2 h intervals) resulted in a 2-3 fold increase in the extracellular concentration of glutamate in the hippocampus; no increase was evident in the striatum or prefrontal cortex. Reverse dialysis of MDMA (100 μM) into the hippocampus also elicited an increase in extracellular glutamate. Treatment with the 5-HT reuptake inhibitor fluoxetine prevented the increase in extracellular glutamate in the hippocampus following the systemic administration of MDMA, as did treatment with the serotonin 5-HT2A/C receptor antagonist ketanserin. Moreover, reverse dialysis of the sodium channel blocker tetrodotoxin did not prevent the increase in extracellular glutamate in the hippocampus. These data support the view that stimulation of 5-HT2A/2C receptors on non-neuronal cells by 5-HT released by MDMA promotes glutamate efflux in the hippocampus.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842073      PMCID: PMC3437747          DOI: 10.1016/j.neuropharm.2012.07.026

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  41 in total

1.  In vitro evidence that 5-hydroxytryptamine increases efflux of glial glutamate via 5-HT(2A) receptor activation.

Authors:  R Meller; P J Harrison; J M Elliott; T Sharp
Journal:  J Neurosci Res       Date:  2002-02-01       Impact factor: 4.164

2.  Low ambient temperature reveals distinct mechanisms for MDMA-induced serotonergic toxicity and astroglial Hsp27 heat shock response in rat brain.

Authors:  Csaba Adori; Rómeó D Andó; Tamás Balázsa; Csaba Soti; Szilvia Vas; Miklós Palkovits; Gábor G Kovács; György Bagdy
Journal:  Neurochem Int       Date:  2011-07-05       Impact factor: 3.921

3.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Authors:  Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau
Journal:  Brain       Date:  2010-05-17       Impact factor: 13.501

4.  The origin and neuronal function of in vivo nonsynaptic glutamate.

Authors:  David A Baker; Zheng-Xiong Xi; Hui Shen; Chad J Swanson; Peter W Kalivas
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

5.  Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis.

Authors:  C Rocher; A M Gardier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-04       Impact factor: 3.000

6.  Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes.

Authors:  Malika Israilova; Fumiko Suzuki; Takashi Tanaka; Takafumi Nagatomo; Takanobu Taniguchi; Ikunobu Muramatsu
Journal:  Pharmacology       Date:  2002-05       Impact factor: 2.547

7.  Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

Authors:  D S Lorrain; C S Baccei; L J Bristow; J J Anderson; M A Varney
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

8.  Drug-induced plasticity contributing to heightened relapse susceptibility: neurochemical changes and augmented reinstatement in high-intake rats.

Authors:  Aric Madayag; Kristen S Kau; Doug Lobner; John R Mantsch; Samantha Wisniewski; David A Baker
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

9.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.

Authors:  R Thomasius; K Petersen; R Buchert; B Andresen; P Zapletalova; L Wartberg; B Nebeling; A Schmoldt
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

Review 10.  Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Methods Mol Med       Date:  2003
View more
  11 in total

1.  MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.

Authors:  Stuart A Collins; Gary A Gudelsky; Bryan K Yamamoto
Journal:  Eur J Pharmacol       Date:  2015-04-30       Impact factor: 4.432

2.  Treadmill running restores MDMA-mediated hyperthermia prevented by inhibition of the dorsomedial hypothalamus.

Authors:  Dmitry V Zaretsky; Maria V Zaretskaia; Pamela J Durant; Daniel E Rusyniak
Journal:  Brain Res       Date:  2015-02-25       Impact factor: 3.252

3.  MDMA decreases glutamic acid decarboxylase (GAD) 67-immunoreactive neurons in the hippocampus and increases seizure susceptibility: Role for glutamate.

Authors:  Courtney L Huff; Rachel L Morano; James P Herman; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Neurotoxicology       Date:  2016-10-20       Impact factor: 4.294

4.  MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density.

Authors:  Sònia Abad; Alberto Fole; Nuria del Olmo; David Pubill; Mercè Pallàs; Fèlix Junyent; Jorge Camarasa; Antonio Camins; Elena Escubedo
Journal:  Psychopharmacology (Berl)       Date:  2013-10-26       Impact factor: 4.530

5.  Crosstalk Among Disrupted Glutamatergic and Cholinergic Homeostasis and Inflammatory Response in Mechanisms Elicited by Proline in Astrocytes.

Authors:  Samanta Oliveira Loureiro; Daniele Susana Volkart Sidegum; Helena Biasibetti; Mery Stefani Leivas Pereira; Diogo Losch de Oliveira; Regina Pessoa-Pureur; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2015-01-13       Impact factor: 5.590

Review 6.  Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  Laura E Halpin; Stuart A Collins; Bryan K Yamamoto
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

7.  MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase.

Authors:  John H Anneken; Jacobi I Cunningham; Stuart A Collins; Bryan K Yamamoto; Gary A Gudelsky
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

8.  3,4-methylenedioxymethamphetamine increases excitability in the dentate gyrus: role of 5HT2A receptor-induced PGE2 signaling.

Authors:  Stuart A Collins; Courtney Huff; Nicolas Chiaia; Gary A Gudelsky; Bryan K Yamamoto
Journal:  J Neurochem       Date:  2016-01-19       Impact factor: 5.372

9.  Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.

Authors:  Oliver G Bosch; Michael Wagner; Frank Jessen; Kai-Uwe Kühn; Alexius Joe; Erich Seifritz; Wolfgang Maier; Hans-Jürgen Biersack; Boris B Quednow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

10.  Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells.

Authors:  Dina Popova; Andréas Forsblad; Sanaz Hashemian; Stig O P Jacobsson
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.